Literature DB >> 34249600

Exploring the inhibitory potentials of Momordica charantia bioactive compounds against Keap1-Kelch protein using computational approaches.

Temitope Isaac Adelusi1, Misbaudeen Abdul-Hammed2, Mukhtar Oluwaseun Idris3, Oyedele Qudus Kehinde1, Ibrahim Damilare Boyenle1, Ukachi Chiamaka Divine1, Ibrahim Olaide Adedotun2, Ajayi Ayodeji Folorunsho4, Oladipo Elijah Kolawole5.   

Abstract

The search for Keap1 inhibitors as potential Nrf2 activator is a way of increasing the antioxidant status of the human cellular environ. In this research, we used in silico methods to investigate Keap1-kelch inhibitory potential of Momordica charantia's bioactive compounds in order to predict their Nrf2 activating potential. ADMET profiling, physicochemical properties, molecular docking, molecular dynamics, and Molecular Mechanics-Poisson Boltzmann Surface Area (g_MMPBSA) free energy calculation studies were executed to drive home our aim. Out of all the bioactive compounds of Momordica charantia, catechin (CAT) and chlorogenic acid (CGA) were selected based on their ADMET profile, physicochemical properties, and molecular docking analysis. Molecular docking studies of CAT and CGA to Keap1 kelch domain showed that they have - 9.2 kJ/mol and - 9.1 kJ/mol binding energies respectively with CAT having four hydrogen bond interactions with Keap1 while CGA had three. Analysis after the 30 ns molecular dynamics simulation revealed that CAT and CGA were both stable, although with minimal conformational alterations at the kelch pocket of Keap1. Finally, MMPBSA calculation of the Gibbs free energy of each amino acid interaction with CAT and CGA revealed that CAT had a higher total binding energy than CGA. Therefore, the Keap1 inhibitory capacities and the molecular dynamic characters of CAT and CGA at the Kelch domain of Keap1 suggest a putative Nrf2 signaling activating prowess. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40203-021-00100-2.
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021.

Entities:  

Keywords:  Keap1; Molecular Mechanics-Poisson Boltzman Surface Area (g_MMPBSA); Molecular dynamics; Momordica charantia

Year:  2021        PMID: 34249600      PMCID: PMC8233444          DOI: 10.1007/s40203-021-00100-2

Source DB:  PubMed          Journal:  In Silico Pharmacol        ISSN: 2193-9616


  56 in total

Review 1.  Molecular mechanisms of the Keap1–Nrf2 pathway in stress response and cancer evolution.

Authors:  Keiko Taguchi; Hozumi Motohashi; Masayuki Yamamoto
Journal:  Genes Cells       Date:  2011-02       Impact factor: 1.891

Review 2.  Principles of early drug discovery.

Authors:  J P Hughes; S Rees; S B Kalindjian; K L Philpott
Journal:  Br J Pharmacol       Date:  2011-03       Impact factor: 8.739

3.  Structures of new cucurbitane-type triterpenes and glycosides, karavilagenins and karavilosides, from the dried fruit of Momordica charantia L. in Sri Lanka.

Authors:  Seikou Nakamura; Toshiyuki Murakami; Junko Nakamura; Hisanori Kobayashi; Hisashi Matsuda; Masayuki Yoshikawa
Journal:  Chem Pharm Bull (Tokyo)       Date:  2006-11       Impact factor: 1.645

4.  Extracts of Momordica charantia suppress postprandial hyperglycemia in rats.

Authors:  Takashi Uebanso; Hidekazu Arai; Yutaka Taketani; Makiko Fukaya; Hironori Yamamoto; Akira Mizuno; Keisuke Uryu; Takahiko Hada; Eiji Takeda
Journal:  J Nutr Sci Vitaminol (Tokyo)       Date:  2007-12       Impact factor: 2.000

Review 5.  hERG trafficking inhibition in drug-induced lethal cardiac arrhythmia.

Authors:  Hisashi Nogawa; Tomoyuki Kawai
Journal:  Eur J Pharmacol       Date:  2014-07-03       Impact factor: 4.432

Review 6.  The Nrf2/Keap1/ARE Pathway and Oxidative Stress as a Therapeutic Target in Type II Diabetes Mellitus.

Authors:  Joshua A David; William J Rifkin; Piul S Rabbani; Daniel J Ceradini
Journal:  J Diabetes Res       Date:  2017-08-20       Impact factor: 4.011

7.  Anti-inflammatory effect of Momordica charantia in sepsis mice.

Authors:  Che-Yi Chao; Ping-Jyun Sung; Wei-Hsien Wang; Yueh-Hsiung Kuo
Journal:  Molecules       Date:  2014-08-21       Impact factor: 4.411

8.  Designing novel possible kinase inhibitor derivatives as therapeutics against Mycobacterium tuberculosis: An in silico study.

Authors:  Mohd Shahbaaz; Anati Nkaule; Alan Christoffels
Journal:  Sci Rep       Date:  2019-03-13       Impact factor: 4.379

9.  p62/Sqstm1 promotes malignancy of HCV-positive hepatocellular carcinoma through Nrf2-dependent metabolic reprogramming.

Authors:  Tetsuya Saito; Yoshinobu Ichimura; Keiko Taguchi; Takafumi Suzuki; Tsunehiro Mizushima; Kenji Takagi; Yuki Hirose; Masayuki Nagahashi; Tetsuro Iso; Toshiaki Fukutomi; Maki Ohishi; Keiko Endo; Takefumi Uemura; Yasumasa Nishito; Shujiro Okuda; Miki Obata; Tsuguka Kouno; Riyo Imamura; Yukio Tada; Rika Obata; Daisuke Yasuda; Kyoko Takahashi; Tsutomu Fujimura; Jingbo Pi; Myung-Shik Lee; Takashi Ueno; Tomoyuki Ohe; Tadahiko Mashino; Toshifumi Wakai; Hirotatsu Kojima; Takayoshi Okabe; Tetsuo Nagano; Hozumi Motohashi; Satoshi Waguri; Tomoyoshi Soga; Masayuki Yamamoto; Keiji Tanaka; Masaaki Komatsu
Journal:  Nat Commun       Date:  2016-06-27       Impact factor: 14.919

10.  PubChem Substance and Compound databases.

Authors:  Sunghwan Kim; Paul A Thiessen; Evan E Bolton; Jie Chen; Gang Fu; Asta Gindulyte; Lianyi Han; Jane He; Siqian He; Benjamin A Shoemaker; Jiyao Wang; Bo Yu; Jian Zhang; Stephen H Bryant
Journal:  Nucleic Acids Res       Date:  2015-09-22       Impact factor: 16.971

View more
  1 in total

1.  Integrated virtual screening and molecular dynamics simulation revealed promising drug candidates of p53-MDM2 interaction.

Authors:  Abdul-Quddus Kehinde Oyedele; Temitope Isaac Adelusi; Abdeen Tunde Ogunlana; Rofiat Oluwabusola Adeyemi; Opeyemi Emmanuel Atanda; Musa Oladayo Babalola; Mojeed Ayoola Ashiru; Isong Josiah Ayoola; Ibrahim Damilare Boyenle
Journal:  J Mol Model       Date:  2022-05-10       Impact factor: 1.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.